<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203228</url>
  </required_header>
  <id_info>
    <org_study_id>2005-002011-24</org_study_id>
    <secondary_id>EBMT 42205525</secondary_id>
    <nct_id>NCT01203228</nct_id>
    <nct_alias>NCT00682396</nct_alias>
  </id_info>
  <brief_title>Dose-reduced Versus Standard Conditioning in MDS/sAML</brief_title>
  <acronym>RICMAC</acronym>
  <official_title>Dose-reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study (RICMAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Group for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial dose reduced conditioning is compared to standard conditioning followed by
      allogeneic stem cell transplantation from related or unrelated donors in patients with MDS or
      secondary AML.

      Conditioning is the very high dose chemotherapy treatment that is given in the days before
      the stem cell transplant.

      The hypothesis is that a dose reduced conditioning will reduce the non-relapse mortality from
      40% to 20% at one year after allogeneic stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>non-relapse mortality</measure>
    <time_frame>every 6 months for safety and in the final analysis at one year after allogeneic stem cell transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>organ related toxicity of conditioning</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +30 after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of aGVHD</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +100 after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of cGVHD</measure>
    <time_frame>every 6 months for safety and in the final analysis at one year after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>every 6 months for safety and in the final analysis at 2 years after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival</measure>
    <time_frame>every 6 months for safety and in the final analysis at 2 years after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>every 6 months for safety and in the final analysis at 2 years after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VOD</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +100 after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection incidence</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +100, 1 year and 2 years after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematopoeitic recovery</measure>
    <time_frame>every 6 months for safety and in the final analysis at day +30 after allogeneic stem cell transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Myeloablative conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced Intensity Conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reduced Intensity Conditioning</intervention_name>
    <description>Busilvex®:
6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)
or (if i.v.-application is not available)
Busulfan:
8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW
plus:
Fludarabine:
5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Myleran</other_name>
    <other_name>Sulphabutin</other_name>
    <other_name>Busulphan</other_name>
    <other_name>Leucosulfan</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Citosulfan</other_name>
    <other_name>Mielevcin</other_name>
    <other_name>Milecitan</other_name>
    <other_name>Fludara</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludura</other_name>
    <other_name>FAMP</other_name>
    <other_name>2-Fluoro-ara-AMP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Myeloablative conditioning</intervention_name>
    <description>Busilvex®:
12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)
or (if i.v.-application is not available):
Busulfan:
16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW
plus:
Cyclophosphamide:
120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Myleran</other_name>
    <other_name>Sulphabutin</other_name>
    <other_name>Busulphan</other_name>
    <other_name>Leucosulfan</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Citosulfan</other_name>
    <other_name>Mielevcin</other_name>
    <other_name>Milecitan</other_name>
    <other_name>cyclophosphamide</other_name>
    <other_name>Procytox</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Claphene</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disease: Cytologically proven primary or therapy-related myelodysplastic syndrome
             (MDS), either as

               -  refractory anaemia (RA) according FAB or RA with or without dysplasia according
                  WHO,

               -  refractory anaemia with ringsideroblasts (RARS) according FAB or RARS with or
                  without dysplasia according WHO,

               -  refractory anaemia with excess of blasts (RAEB) according FAB or RAEB I or RAEB
                  II according WHO,

               -  refractory anaemia with excess of blast in transformation (RAEB T) according FAB,

               -  CMML (dysplastic type) according WHO,

          -  or secondary acute myeloid leukaemia (sAML).

          -  Blast count &lt; 20 percent in bone marrow with or without chemotherapy at time of
             transplantation.

          -  Patient eligible for standard and dose-reduced conditioning as per local guideline.

          -  Patient age 18 - 60 years if donor is a HLA-matched unrelated donor (HLA-A, HLA-B,
             HLA-DRB1 and HLA-DQB1) (one mismatch allowed):

          -  Patient age 18 - 65 years if donor is a HLA-matched related donor ((HLA-A, HLA-B,
             HLA-DRB1 and HLA-DQB1) (one anti¬gen-mismatch allowed):

          -  No major organ dysfunction.

          -  Written informed consent of the patient.

        Exclusion Criteria:

          -  Blasts &gt; 20 % in bone marrow at time of transplantation

          -  No written informed consent.

          -  Central nervous involvement.

          -  Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as

          -  Total bilirubin, SGPT or SGOT &gt; 2 times upper the normal level.

          -  Left ventricular ejection fraction &lt; 30 %.

          -  Creatinine clearance &lt; 30 ml/min.

          -  DLCO &lt; 35 % and/or receiving supplementary continuous oxygen.

          -  Positive serology for HIV.

          -  Pregnant or lactating women.

          -  Patients with a life-expectancy of less than six months because of another
             debilitating disease.

          -  Serious psychiatric or psychological disorders.

          -  Invasive fungal infection at time of registration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kröger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Axel R Zander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Hamburg-Eppendorf, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ghulam J Mufti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Robin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Saint-Louis Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathrin Haifa Al-Ali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dietger Niederwieser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giorgio Lambertenghi Deliliers</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Ospedale Maggiore of Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domink Heim, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liisa Volin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Guidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Careggi Hospital - Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Augustin Ferrant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St. Luc Bruxelles, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Afanasyer Boris</last_name>
    <role>Principal Investigator</role>
    <affiliation>SPB Pavlov Medical Univ, St. Petersburg, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kai Hubel</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Dreger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ Hospital Heidelberg - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Gramatzlle</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Münster - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerhard Behre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martin-Luther-Universitaet Halle-Wittenberg - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Gramatzlle</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ Hospital Kiel - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allione Bernardino</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santi Antonio E Biagio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Munster</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santi Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University MC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb State I. Pavlov Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.ebmt.org/Contents/Pages/Default.aspx</url>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reduced Intensity conditioning</keyword>
  <keyword>Myeloablative conditionig</keyword>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>MUD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

